Evidence map›Paper›PMID 27473082›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

A novel VHLα isoform inhibits Warburg effect via modulation of PKM splicing.

Yanbin Liu, Haixia Yang, Lin Li, She Chen, Feifei Zuo, Liang Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. HNRNPA2B1: a novel target in pulmonary arterial hypertension.Frontiers in cardiovascular medicine · 2025
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yanbin LiuCollaborative Innovation Center of Cancer Medicine, National Institute of Biological Sciences, Beijing, Beijing, 102206, China. yanbliu2012@sina.cn.
Haixia YangNational Institute of Biological Sciences, Beijing, Beijing, 102206, China.
Lin LiNational Institute of Biological Sciences, Beijing, Beijing, 102206, China.
She ChenNational Institute of Biological Sciences, Beijing, Beijing, 102206, China.
Feifei ZuoNational Institute of Biological Sciences, Beijing, Beijing, 102206, China.
Liang ChenCollaborative Innovation Center of Cancer Medicine, National Institute of Biological Sciences, Beijing, Beijing, 102206, China. chengliang@nibs.ac.cn.
National Institute of Biological Sciences, Beijing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Von Hippel-Lindau (VHL) is the most frequently mutated gene in clear cell renal carcinoma. Here, we identified a novel translational variant of VHL, termed VHLα, initiated from an alternative translational start site upstream and in frame with the ATG start codon. We showed that VHLα interacts with and regulates heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1), which consequently modulates pyruvate kinase transcript splicing and reprograms cellular glucose metabolism. Our study demonstrated that a novel VHL isoform may function as a tumor suppressor through inhibiting the Warburg effect.

Indexed as

GlycolysisAmino Acid SequenceAnimalsBase SequenceBiomarkers, TumorBlotting, WesternCRISPR-Cas SystemsGlucoseHumansImmunoprecipitationLactic AcidMiceMice, Inbred NODMice, SCIDNeoplasmsProtein IsoformsBiomarkers, TumorGlucoseLactic AcidProtein IsoformsPyruvate KinaseVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinAlternative translationGlucose metabolismhnRNPA2B1Pyruvate kinaseVHL

Identifiers

PMID27473082
OpenAlexW2489488238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.